공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

췌장암 : 시장 기회 분석과 예측(-2029년)

Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029

리서치사 GlobalData
발행일 2020년 12월 상품 코드 979396
페이지 정보 영문 146 Pages
가격
US $ 10,995 ₩ 12,771,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 21,990 ₩ 25,543,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 32,985 ₩ 38,315,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


췌장암 : 시장 기회 분석과 예측(-2029년) Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029
발행일 : 2020년 12월 페이지 정보 : 영문 146 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

췌장암은 현재 세계에서 일곱번째로 많은 암 관련 사인이며, 2018년에는 432,242명이 사망한 것으로 보고되고 있습니다. 외분비성 췌장암으로 분류되는 췌장선암(PDAC)이 가장 일반적인 유형의 췌장암이며, 전체 췌장암 진단의 80%를 차지하고 있습니다.

세계 주요 8개국의 췌장암(Pancreatic Cancer) 시장을 조사했으며, 질환 개요, 병인/병태생리, 진단 사례 추이와 예측, 현재의 치료 옵션, 충족되지 않은 욕구, 파이프라인 동향, 출시 제품 동향, 시장 규모 추이와 예측, 향후 전망 등의 정보를 정리하여 전해드립니다.

제1장 목차

제2장 개요

제3장 서론

제4장 질환 개요

  • 병인/병태생리
  • 분류/Staging System

제5장 역학

  • 질병의 배경
  • 위험인자/동반질환
  • 세계 동향과 역사적 동향
  • 예측 조사 방법
  • 췌장암 역학 예측
    • 췌장암 진단 사례
    • PDAC 진단 사례
    • PDAC 진단 사례 : 남녀별
    • PDAC 진단 사례 : 연령별
    • PDAC 진단 사례 : 단계별
    • 가족성 PDAC 진단 사례 : 생식세포 변이별
    • PDAC 진단 사례 : KRAS·NTRK 유전자 변이별
    • PDAC 진단 사례 : PD-L1 발현별
    • PDAC 5개년 진단 환자수
  • 검토

제6장 현재의 치료 옵션

제7장 충족되지 않은 욕구와 시장 기회 평가

제8장 R&D 전략

  • 개요
  • 임상시험 설계

제9장 파이프라인 평가

  • 개요
  • 혁신적인 초기 접근
    • 키메라 항원 수용체(CAR) T세포 치료
    • 유전자 치료
    • 암 백신
  • 개발 중인 기타 약제

제10장 파이프라인 평가 분석

  • 주요 파이프라인약 임상 벤치마킹
  • 주요 파이프라인약 상업적 벤치마킹
  • 경쟁 평가
  • TOP 라인 10개년 예측
    • 미국
    • EU 5개국
    • 일본
    • 중국 도시
    • 결론

제11장 부록

LSH 21.01.07

List of Tables

List of Tables

  • Table 1: Pancreatic Cancer: Key Metrics in the 8MM
  • Table 2: Selected Genetic Syndromes with Associated Pancreatic Cancer Risk
  • Table 3: AJCC TNM classification System for Pancreatic Cancer
  • Table 4: AJCC TNM Staging System for Pancreatic Cancer
  • Table 5: Risk Factors and Comorbidities for PDAC
  • Table 6: Current Leading Treatments for Pancreatic Cancer, 2019
  • Table 7: Key Pipeline Agents in Development for Pancreatic cancer, 2019-2029
  • Table 8: Key Phase II/III Clinical Trials in Pancreatic Cancer, 2019-2029
  • Table 9: Comparison of Therapeutic Classes in Development for Pancreatic Cancer, 2019-2029
  • Table 10: Leading Pharmaceutical Companies Innovating in CAR-T Therapy in 2019
  • Table 11: Drugs in Development for Pancreatic Cancer, 2019-2029
  • Table 12: Clinical Benchmarking of Key Marketed & Pipeline Products - First Line
  • Table 13: Clinical Benchmarking of Key Marketed & Pipeline Products - Second Line
  • Table 14: Commercial Benchmarking of Key Marketed & Pipeline Products - First Line
  • Table 15: Commercial Benchmarking of Key Marketed & Pipeline Products - Second Line
  • Table 16: Key Events Impacting Sales for Pancreatic Cancer in the US, 2019-2029
  • Table 17: Pancreatic Cancer Market - Global Drivers and Barriers, 2019-2029
  • Table 18: Key Historical and Projected Launch Dates for Pancreatic Cancer
  • Table 19: Key Historical and Projected Patent Expiry Dates for Pancreatic Cancer
  • Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Pancreatic Cancer in 2019 and 2029
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, FOLFIRINOX - First Line
  • Figure 3: Competitive A

Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029

Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses.

The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX and gemcitabine-based therapies, which are considered to be gold standard for pancreatic cancer. In patients exhibiting genetic mutations, targeted therapies such as Vitrakvi (larotrectinib), Rozlytrek (entrectinib), Poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib), and Keytruda (pembrolizumab) are currently included in treatment guidelines across the 8MM. CP-613 (devimistat) and TAK-931 (simurosertib) are the lead pipeline candidates in 1L setting. This indication will also se introduction of 2 strong pipeline agents in 3L setting.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 10 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
  • Among the late-stage pipeline products and marketed agents, TAK-931 (simurosertib) and CP-613 (devimistat) are expected to generate the greatest revenues over the forecast period.
  • The most important unmet needs in the pancreatic cancer market include: effective treatment options that prolong survival in advanced or metastatic settings, early diagnosis and tumor targeting drugs with novel mechanisms of actions.

KEY QUESTIONS ANSWERED

  • Ten late-stage pipeline agents are going to enter the pancreatic cancer market from 2019 onwards. Will the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in pancreatic cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

  • Overview of pancreatic cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline pancreatic cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting pancreatic cancer therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
  • Analysis of the current and future market competition in the global pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global pancreatic cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global pancreatic cancer therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pancreatic Cancer: Executive Summary

  • 2.1 Global Pancreatic Cancer Market Expected to Grow at 11.5% CAGR to $5.4B During 2019-2029
  • 2.2 Assessing Viability of Novel Tumor Targeting Therapies - A Key Focus of Current Clinical Development
  • 2.3 Lack of Effective Treatment Options - Highest Unmet Need in PDAC
  • 2.4 High Opportunity for Pipeline Agents Demonstrating Increased Overall Survival
  • 2.5 Targeted Therapies Provide a Brighter Outlook for PDAC
  • 2.6 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
    • 5.4.3 Diagnosed Incident Cases of Pancreatic Cancer and PDAC
    • 5.4.4 Diagnosed Incident Cases of PDAC by Stages
    • 5.4.5 Diagnosed Incident Cases of PDAC by Familial PDAC by Germline Mutation
    • 5.4.6 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutation
    • 5.4.7 Diagnosed Incident Cases of PDAC by PD-L1 Expression
    • 5.4.8 Five-Year Diagnosed Prevalent Cases of PDAC
  • 5.5 Epidemiological Forecast for Pancreatic Cancer, 2019-2029
    • 5.5.1 Diagnosed Incident Cases of Pancreatic Cancer
    • 5.5.2 Diagnosed Incident Cases of PDAC
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of PDAC
    • 5.5.4 Age-Specific Diagnosed Incident Cases of PDAC
    • 5.5.5 Diagnosed Incident Cases of PDAC by Stage at Diagnosis
    • 5.5.6 Diagnosed Incident Cases of Familial PDAC by Germline Mutations
    • 5.5.7 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Mutations
    • 5.5.8 Diagnosed Incident Cases of PDAC by PD-L1 Expression
    • 5.5.9 Five-Year Diagnosed Prevalent Cases of PDAC
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 COVID-19 Impact
    • 5.6.3 Limitations of Analysis
    • 5.6.4 Strengths of Analysis

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Early Detection
  • 7.3 Expansion of Eligible Patient Population and Need for the Discovery of New Biomarkers
  • 7.4 Increased Availability of Treatment Options
  • 7.5 Treatment Options in the Third-Line Setting
  • 7.6 Prolonged Life Expectancy/Survival

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Drugs Targeting Tumor Immune Evasion Mechanisms
    • 8.1.2 Expansion into Neoadjuvant and Adjuvant Settings
    • 8.1.3 Explore Viability of Novel Targets and Mechanism of Action
    • 8.1.4 Reformulation of Marketed Drugs
    • 8.1.5 Therapy Sequencing
  • 8.2 Clinical Trials Design
    • 8.2.1 Key Clinical Trials
    • 8.2.2 Primary and Secondary Endpoints
    • 8.2.3 Trial Design Characteristics

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Innovative Early-Stage Approaches
    • 9.2.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy
    • 9.2.2 Gene therapy
    • 9.2.3 Cancer vaccine
  • 9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

  • 10.1 Clinical Benchmark of Key Pipeline Drugs
  • 10.2 Commercial Benchmark of Key Pipeline Drugs
  • 10.3 Competitive Assessment
  • 10.4 Top-Line 10-Year Forecast
    • 10.4.1 US
    • 10.4.2 5EU
    • 10.4.3 Japan
    • 10.4.4 Urban China
    • 10.4.5 Conclusion

11 Appendix

Back to Top
전화 문의
F A Q